CD274 and neoplasm: These drugs can bind to either PD-1 or PD-L1, blocking the inhibitory effect of tumor cells on immune function and restoring the activity of T cells, ultimately leading to a more robust immune response against the tumor and improved outcomes for patients with cancer (Shen and Zhao, 2018; Korman et al., 2022).